---
schema_version: "secwatch.filing_event.v1"
accession: "0001759425-26-000021"
form_type: "8-K/A"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2026-04-08T23:59:59+00:00"
generated_at: "2026-05-15T06:55:10.573234+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Mirum completes acquisition of Bluejay Therapeutics with $268.5M PIPE; Bluejay reports 2025 net loss of $101.7M

## Summary
- Concurrent PIPE raised $268.5M gross at $68.48/sh including pre-funded warrants.
- Bluejay 2025 audited: net loss $101.7M, R&D $87.1M, total assets $85.6M, accumulated deficit $190M.
- Bluejay had substantial doubt about going concern; Mirum committed to fund operations post-close.
- Lead candidate brelovitug (BJT-778) for chronic hepatitis delta is in clinical development.
- Pro forma financials for combined entity filed; acquisition closed Jan 23, 2026.

## SEC filing metadata
- accession: 0001759425-26-000021
- form_type: 8-K/A
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2026-04-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000021/0001759425-26-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000021/mirm-20260123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759425-26-000021
- JSON: https://secwatch.observer/filing/0001759425-26-000021.json
- Plain text: https://secwatch.observer/filing/0001759425-26-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.